[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339585-105":59,"doc-detail-339585-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","circulating-tumor-dna-in-genitourinary-cancers-detection-prognostics-and-therapeutic-implications","Circulating Tumor DNA in Genitourinary Cancers - Detection, Prognostics, and Therapeutic Implications","","Circulating tumor DNA (ctDNA) is presented as a non-invasive approach for detecting and monitoring genitourinary (GU) cancers, including prostate, bladder, and renal cell carcinoma, using blood or urine liquid biopsies. The text explains how ctDNA assays can support early detection, provide prognostic signals, track real-time treatment response, and identify residual disease and relapse. It also outlines how ctDNA analyses can reveal actionable genetic, epigenetic, and mutation-based alterations, while emphasizing that clinical utility still requires further validation and additional research.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/circulating-tumor-dna-in-genitourinary-cancers-detection-prognostics-and-therapeutic-implications/339585/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/circulating-tumor-dna-in-genitourinary-cancers-detection-prognostics-and-therapeutic-implications/339585.png","ImageObject",300,407,{"name":92,"@type":93},"Maeve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"How is circulating tumor DNA (ctDNA) obtained in genitourinary cancers?","Question",{"text":113,"@type":114},"ctDNA can be detected from blood or urine samples, using non-invasive “liquid biopsy” approaches.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What clinical purposes does ctDNA serve for GU cancers?",{"text":118,"@type":114},"ctDNA is used for early detection, prognostication, assessment of real-time treatment response, and detection of residual disease and relapse.",{"name":120,"@type":111,"acceptedAnswer":121},"What information can ctDNA assays reveal?",{"text":122,"@type":114},"ctDNA analysis can identify common cancer mutations, novel genomic alterations, and epigenetic modifications that reflect tumor biology.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},339585,1790171775,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},5909877438554,"https://ap-avatar.wpscdn.com/avatar/5600025385ad2bf12a7?_k=1778553567797529272","cancers   \nReview  \nCirculating Tumor DNA in Genitourinary Cancers: Detection, Prognostics, and Therapeutic Implications  \nMargo B. Gerke 1, Caroline S. Jansen 1,2 and Mehmet A. Bilen 2,3, *  \nCitation: Gerke, M.B.; Jansen, C.S.; Bilen, M.A. Circulating Tumor DNA in Genitourinary Cancers: Detection, Prognostics, and Therapeutic Implications. Cancers 2024, 16, 2280 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)cancers16122280  \nAcademic Editors: Barbara Mroczko and Monika Gudowska-Sawczuk  \nReceived: 25 May 2024  \nRevised: 18 June 2024  \nAccepted: 18 June 2024  \nPublished: 20 June 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Emory University School of Medicine, Atlanta, GA 30322, USA; [mgerke@emory.edu](mgerke@emory.edu) (M.B.G.); [carey.jansen@emory.edu](carey.jansen@emory.edu) (C.S.J.)  \n2 Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA  \n3 Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA  \n* [Correspondence: mehmet.a.bilen@emory.edu](Correspondence: mehmet.a.bilen@emory.edu); Tel.: +1-404-778-3693; Fax: +1-404-778-8584  \nSimple Summary: Circulating tumor DNA (ctDNA) is a non-invasive method of identifying and monitoring genitourinary cancers, including prostate, bladder, and renal cell carcinoma, via blood or urine samples. CtDNA introduces a potential method for cancer screening. If detected, ctDNA may reveal genetic alterations that have prognostic value. As treatment options for genitourinary cancers progress towards accounting for tumor genetic profiles, ctDNA may predict which patients have improved responses to therapeutic targets. CtDNA may play an important role in surveillance after tumor resection and may be used to reveal mechanisms of treatment resistance. The clinical utility of ctDNA has yet to be established. Significantly more research is needed to understand the utility ctDNA has in clinical practice.  \nAbstract: CtDNA is emerging as a non-invasive clinical detection method for several cancers, including genitourinary (GU) cancers such as prostate cancer, bladder cancer, and renal cell carcinoma (RCC) . CtDNA assays have shown promise in early detection of GU cancers, providing prognostic information, assessing real-time treatment response, and detecting residual disease and relapse. The ease of obtaining a “liquid biopsy” from blood or urine in GU cancers enhances its potential to be used as a biomarker. Interrogating these “liquid biopsies” for ctDNA can then be used to detect common cancer mutations, novel genomic alterations, or epigenetic modifications. CtDNA has undergone investigation in numerous clinical trials, which could address clinical needs in GU cancers, for instance, earlier detection in RCC, therapeutic response prediction in castration-resistant prostate cancer, and monitoring for recurrence in bladder cancers. The utilization of liquid biopsy for ctDNA analysis provides a promising method of advancing precision medicine within the field of GU cancers.  \nKeywords: circulating tumor DNA; prostate cancer; bladder cancer; renal cell carcinoma; liquid biopsy; genitourinary cancers; tumor biomarkers  \n1. Introduction  \nCtDNA is released through tumor cell apoptosis and necrosis with an estimated half-life of 16 min to 2.5 h [1] . CtDNA release is tumor-dependent, with factors such as size, metastasis, and stage impacting the amount of ctDNA found in blood [2,3] . Asthe genetic aberrations of a tumor evolve over time, as a result of therapy or with disease recurrence or progression, ctDNA represents an opportunity for real-time molecular profiling that would otherw","cbCaip8YeNI1XFhs","https://ap.wps.com/l/cbCaip8YeNI1XFhs","pdf",1316646,28,"English","# Simple Summary\n# Abstract\n# Keywords\n# Introduction","[{\"question\":\"How is circulating tumor DNA (ctDNA) obtained in genitourinary cancers?\",\"answer\":\"ctDNA can be detected from blood or urine samples, using non-invasive “liquid biopsy” approaches.\"},{\"question\":\"What clinical purposes does ctDNA serve for GU cancers?\",\"answer\":\"ctDNA is used for early detection, prognostication, assessment of real-time treatment response, and detection of residual disease and relapse.\"},{\"question\":\"What information can ctDNA assays reveal?\",\"answer\":\"ctDNA analysis can identify common cancer mutations, novel genomic alterations, and epigenetic modifications that reflect tumor biology.\"}]","Circulating Tumor DNA in Genitourinary Cancers - Detection, Prognostics, and Therapeutic Implications | PDF",1790031122,71,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ea13de448a57a6ea969fd86a78d8ea45.webp",983,1390,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/82b97cfef66bd81ffb5dc0ab2bf1acff.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6c2bca0dbf169dc18f7846d5ca2f5caa.webp",981,1387,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f65172a38d89c82cfbeea2a23871a4b1.webp",980,1385]